Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ChartData by YCharts Production is difficult and it takes a long time The part in this letter that really disappointed me is that ramping up production is extremely difficult. It turns out that the length of time it takes to produce remdesivir is many months at the least. Per Gilead: It is a linear process that requires specialized chemistry and multiple chemical reactions, some of which can take several weeks to complete. It also calls for scarce raw materials as well as sterile manufacturing capabilities with limited global capacity, which are needed to make finished vials ready for administration to patients. Gilead did manage to find ways to cut production times by as much as 50% but end-to-end manufacturing still takes about six months. It has been previously known that Gilead repurposed one of its own facilities to manufacture remdesivir. From this letter I learned, they are repurposing multiple of their own facilities. Gilead is also working with external manufacturers to ramp up production around the globe. Glimmers of hope With this letter, Gilead announced it is giving away 1.5 million individual doses of Remdesivir. Currently, they are trialing 5-day and 10-day treatment courses. So this could translate into a minimum of 140,000 patients getting treated and at best 280,000 patients. My expectation, which is highly speculative, primarily based on reading one study that only had a few people on Remdesivr, I'd expect most COVID-19 patients can be treated with a 5-day course. But a segment of 10%-40% likely requires a 10-day course. Again, I could be totally wrong and we may see 10-day courses as a standard treatment. Economics If Gilead is giving away 1.5 million doses, it implies it is going to charge after that. In my opinion, the company is being enormously generous but they are going to be vilified no matter what. It is viewed as unseemly to make money off a pandemic by a certain amount of the population. I think we should be happy to be enormously thankful if there's a treatment and we can shell out some dollars for a cure. I don't mean to minimize the challenges this will pose to any one's individual budget. I can easily imagine it is in the best interest of nations if the government covers any and all COVID-19 bills. It is going to be a lot cheaper than doing series after series of $2 trillion stimulus plans. At 300k therapies per month and a therapy being anywhere between $500 and $5000 (at 80% gross margins), this could still be a significant therapy to Gilead's bottom line. This translates into between $150 million and $1.5 billion worth of revenue per month. That's between $1.8 billion and $18 billion of revenue. If it is the former Gilead has run a bit too far (although it does not look to me like a way overvalued stock even in that scenario given it started from quite an attractive level). If the price of therapy leans more towards the $5k range, I believe Gilead has a lot of room to run. A lot depends on the competition and the trajectory of COVID-19. There's no reason for the ceiling to be $5k but that's the highest number I've seen mentioned. Between $1.8 billion and $18 billion of annual revenue could obviously be significant to Gilead: ChartData by YCharts Gross profit margins in pharma tend to be really good. The highest costs are usually associated with research and development and especially the research and development that ultimately leads nowhere.
nowhere. ChartData by YCharts At high margins, you can imagine any revenue streams would translate into significant EBITDA. Again, unfortunately, the total addressable market is large enough that the impact on Gilead's bottom line could be large. If Remdesivir is approved, I can easily see this therapy contribute between $1 billion up to $26 billion to Gilead's bottom line. ChartData by YCharts EBITDA would fall off through time after that but not necessarily completely disappear. Increasingly, I'm of the inclination SARS-CoV-2 will end up endemic on a global scale. For example, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, recommends drug manufacturers should take the risk to ramp up production ahead of trials to prepare for COVID-19 becoming a seasonal occurrence. According to Richard Preston, author of The Hot Zone. There is a pattern of viruses jumping from animal to the human species. It is the third coronavirus in a relatively short time to have done so. Urbanization and globalization turn novel viruses into potential global threats like COVID-19 turned out to be. The virus that causes COVID-19 will potentially be endemic to our species. Odds are there will be future coronavirus threats. remdesivir is specifically interesting to me because so far it has shown to be extremely effective against any coronavirus it has been tested on in vitro and in vivo. How will things look in the fall? Part of the Gilead letter that depressed me is that a company with such great expertise in virology as Gilead, is ramping up production to a level of 300K/month by October. That means they believe there's a good chance we aren't done with this problem by then and still need treatment at scale. Cases are increasing by 80k a day currently (obviously this is gated by test capabilities around the globe, actual is in all likelihood much higher). Again, enormous uncertainty around the trajectory and which geographies it will strike. Maybe the number of cases is going to decline as spring heats up or the summer rolls around. Let's just say I wouldn't buy any airline stocks, or companies that are dependent on events and or restaurants any time soon. A vaccine is likely still a long time away. Think at least a year from now. Then there is the question around ramping up production of that vaccine. If remdesivir is a solid therapy, a vaccination may not actually become all that standard. With vaccines there's a slice of the population that's opposed to that to begin with. I'm of the opinion that the mortality rate of COVID-19 is unacceptably high given the ease with which it spreads under normal living conditions. I've seen people point to the mortality rate and say that's not worth the economic sacrifice. That's a grave mistake for several reasons, most importantly: 1) There are a lot of uncertainties around much of the data, meaning you should err on the side of caution. 2) The mortality rate is "low" because of extraordinary efforts by healthcare workers, off-label therapies being applied and because we have an idea which groups are most at risk (there are senior homes where the staff voluntarily locked down along with the inhabitants). 3) For up to 15% of patients it is a very nasty disease even though they may not ultimately lose their lives. 4) Most countries (outside Asia) are managing the spread of the disease (more or less successful) based on intensive care capacity. A rather large number of patients require intensive care and if the standard of care deteriorates because of the volume of patients coming in you will see the mortality rate increase enormously. On the other hand, the mortality rate is higher than it is ultimately likely to end up at because of 1) lack of testing means we are missing a lot of cases (this effect is huge). On balance, for what it's worth, I unequivocally support government measures to delay the speed at which it spreads even though there is a severe economic cost. If healthcare systems are not swamped Remdesivir works well. Perhaps other therapies work well (Maybe chloroquine and filavapir). A large slice of the population developed antibodies organically we may not even see a huge uptake of vaccination programs. Perhaps primarily focused on at-risk groups. The point of all this is that there is a lot of uncertainty around the economics around Remdesivir. Many sell-side analysts are treating this as a one-off small revenue opportunity. Unfortunately, I think there's a good chance this will be a one-off massive revenue opportunity and it could continue to be a significant revenue stream for years to come. Key takeaways for investors This letter will allow analysts to start pricing in remdesivir sales quite accurately as soon as it's confirmed good-to-go (which I expect this month). Subsequently, expect updated notes coming out of the likes of Bank of America (BAC), Goldman Sachs (GS) et all. The other key takeaway is that it seems extremely likely that remdesivir is actually effective. Gilead has treated over 1700 patients. Apparently, the medical community keeps requesting this therapy all the time. In my earlier articles on this subject, I've given myriad anecdotal examples of patients that were treated successfully. There are also other soft-factors that point to potential effectiveness: What The First 12 U.S. COVID-19 Patients Tell Us About Remdesivir What The First 12 U.S. COVID-19 Patients Tell Us About Remdesivir 25-3-2020 12 Reasons Remdesivir is my best COVID-19 bet 12 Reasons Gilead With Remdesivir Is My Best COVID-19 Bet 16-3-2020 Economics of Remdesivir Gilead: Remdesivir's Potential Most Dependent On COVID-19 Spread 1-3-2020 17 reasons I'm confident Remdesivir is effective 17 Reasons Why I'm Confident Gilead's Remdesivir Will Work Against COVID-19 27-2-2020 Market is underestimating COVID-19 and Gilead is an opportunity Gilead: Potential Hedge If Covid-19 Is Taken More Seriously 17-2-2020 5 reasons why Remdesivir is likely to be effective Gilead Sciences: 5 Reasons Remdesivir Is Likely To Be Effective Against The Wuhan Coronavirus 10-2-2017 These all were published exclusively for subscribers at an earlier date. Gilead is also giving away 140k treatments. They are specifically earmarking these for severe cases: The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility. Providing our existing supplies at no charge is the right thing to do, to facilitate access to patients as quickly as possible and in recognition of the public emergency posed by this pandemic. This just screams to me they are aware it is (at least somewhat) effective in severe cases. For people who have access to the trial data, it should be more or less blindingly obvious whether Remdesivir is effective. Based on patient anecdotes and the study into the first batch of U.S. patients I'm under the impression this is not a therapy where 51% of patients benefit.
Gilead is making it reserving the doses it gives away specifically for people that are the hardest hit. That's the toughest group to cure with an antiviral that counters replication. I don't think they would do this if they were uncertain about its effectiveness. They would probably do it but not specifically highlight it in a letter signed by the CEO. In retrospect, it would look ridiculous. Why I'm holding Gilead What I'm planning to do is to add some Gilead exposure as the share price goes towards $70 and I sell some as it is around $80. When initially recommending this around February 5 I acquired a larger position. As the stock price has moved up it has also become much more clear that COVID-19 is a serious problem. But given where things stand now I'm fine with an average-sized position near $80. At $66 I thought there was very little downside risk compared to the upside (I traded around earnings to avoid its impact). But with actual results coming up (which I'm very confident about), the difficulty of manufacturing, the apparent competition from chloroquine and filavapir as well as the stock having run-up while its peer group has collapsed the risk/reward is slightly less attractive to me. Gilead remains attractive to me at $78.21 but is not a screaming buy. Check out the Special Situation Investing report if you are interested in uncorrelated returns. I look at mergers & acquisitions, spin-offs, companies with buyback programs, rights offerings as well as unique opportunities like Gilead today, which is so well positioned with its Remdesivir cure.
Gilead Sciences heeft de productie van zijn experimentele coronavirusgeneesmiddel opgevoerd, vanwege de overweldigende vraag na de golf van infecties wereldwijd. Het aandeel steeg voorbeurs 2,6 procent.www.iex.nl/Forum/Topic/1280654/333/Do...
Gilead teams up with Second Genome to ID biomarkers and IBD candidates Apr. 6, 2020 6:45 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor Gilead Sciences (NASDAQ:GILD) enters into a four-year collaboration with Second Genome aimed at identifying biomarkers associated with clinical response to up to five of Gilead's pipeline candidates in inflammation, fibrosis and other diseases and to identify potential new targets and candidates for inflammatory bowel disease (IBD). Second Genome will leverage its proprietary Microbiome Analytics Platform to identify biomarkers and will combine additional discovery and development tools to to identify targets and candidates for IBD. Under the terms of the agreement, Second Genome will receive $38M upfront, up to $300M in milestones for each of the five programs and success-based milestones for each validated biomarker. Gilead will have the option to in-license global rights for up to five programs for all diseases and all biomarkers. Shares up 2% premarket on light volume.
Mooie nieuwsberichten, je zou zeggen dat de koers daarmee door de weerstand van de vorige toppen kan breken.
Die mooie berichten helpen vandaag de koers niet
Wat een verschil inderdaad tussen voorbeurs (+2%) en tijdens de beurs (-2%). Volgens mij vooral doordat de hele markt weer risk on ging. Doet mijns inziens niets af aan gunstige vooruitzichten gilead.
Ralph01A schreef op 6 april 2020 21:12 :
Wat een verschil inderdaad tussen voorbeurs (+2%) en tijdens de beurs (-2%). Volgens mij vooral doordat de hele markt weer risk on ging. Doet mijns inziens niets af aan gunstige vooruitzichten gilead.
I agree Sterker net als galapagos goed bezig heb ook vertrouwen in O day zelfde kaliber als Onno
KBC Bolero laat weten dat Cantor Fitzgerard (American Financial Services) Gilead op n koop heeft staan, vanwege Remdesivir en pijplijn. Naar 86$ van 78$.
Ik hoop it nog steeds, maar de koersbeweging is neerwaarts vandaag
Summary Gilead’s remdesivir has a significant time advantage over competitor therapeutics. Achieving standard of care status first is highly advantageous in this healthcare crisis. Other COVID-19 therapeutics may struggle to compete with remdesivir, should it be approved first. Weaknesses in the chloroquine/hydroxychloroquine story are emerging. Gilead is a high-quality company with a solid balance sheet.
Innovation Gilead & Forty Seven: Committed to Creating Possible for People Living with Cancer Stories@Gilead - April 07, 2020 Gilead today completed its acquisition of Forty Seven, a clinical-stage immuno-oncology company. The acquisition will help Gilead strengthen its oncology research and development portfolio and adds Forty Seven’s investigational lead product candidate, magrolimab, which is being tested in a number of hematological cancers. Forty Seven was founded by scientists at Stanford University who uncovered the fundamental role of the CD47 receptor in cancer. CD47 is a protein that can be found on many cells and is overexpressed by various types of cancerous tumors. The protein is thought to send a signal that allows cancer to escape elimination by the body’s immune system. Blocking CD47 has the potential to block that signal, activating the immune system to identify and then eliminate cancer cells. Investigational magrolimab is being studied in myelodysplastic syndrome, non-Hodgkin lymphoma and acute myeloid leukemia. The investigational candidate has the potential to be a foundational molecule in Gilead’s immuno-oncology portfolio, as the company seeks to deliver 10 transformative medicines across its therapeutic areas in the next 10 years. “We view oncology as a critical area for our growth and this is an important step toward our goal of improving outcomes for patients living with cancer,” says Gilead Chief Medical Officer Merdad Parsey. “Magrolimab is a great example of an investigational therapeutic with the potential to transform the treatment of myelodysplastic syndrome and other hematological diseases. We will continue to build a portfolio that has assets with similar potential to transform care for people with certain types of cancer who need additional therapeutic options.” Gilead and Forty Seven announced the deal in early March and will now begin working together to integrate the companies. The teams will collaborate on the development of magrolimab and explore how Forty Seven’s expertise in immuno-oncology can accelerate Gilead’s work to advance new therapies to help people living with cancer. “There are many similarities between Gilead and Forty Seven – a patient-centered approach, fast-paced and energetic environment and tendency to be inquisitive when it comes to science,” says Forty Seven President & CEO Mark McCamish. “By coming together, our teams can unify our shared pursuit of meaningful innovation in immuno-oncology to help patients defeat their cancer.” Magrolimab is an investigational agent and has not been approved for use by any regulatory agency globally. Its safety and efficacy have not been establishe
Dit van Stocktwits afgeplukt.. KamiCook 08:26 AM $GILD saw on LinkedIn the other day one insider daying his friend was working on production of Rem and thet he works 24/7 and that he produced two batches already. The message was ina comment to an article about ranping up pruduction. He said he was proud and so on... I was trying to find it again to post here, but you know what... that message has now dissapeared! There is a strict control on the info seems like 2 KamiCook Bullish 08:08 AM $GILD Gilead always makes Rem-related announcements on Saturdays. If the trial result was out last Friday, I am guessing the first to know would be FDA. It would put FDA in an uncomfortable situation if GILD released the succesful data. The pressure will be on them. Obviously they didn't have time to make any announcement last Saturday. Instead they just send a confident message they are ramping up production. My opinion the news will come out on Saturday per current tradution, with a follow up FDA approval on Sunday or Monday. There might be some conditions to the approval, until the other studies are completed. Thoughts?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)